Cargando…
Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer
BACKGROUND: Enzyme replacement therapy (ERT) with α-galactosidase A (α-Gal A) is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease. However, ERT has limitations of a short half-life, requirement for frequent administration, and limited eff...
Autores principales: | Choi, Jin-Ok, Lee, Mi Hee, Park, Hae-Young, Jung, Sung-Chul |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861641/ https://www.ncbi.nlm.nih.gov/pubmed/20398385 http://dx.doi.org/10.1186/1423-0127-17-26 |
Ejemplares similares
-
Protective Effect of Recombinant Adeno-Associated Virus 2/8-Mediated Gene Therapy from the Maternal Hyperphenylalaninemia in Offsprings of a Mouse Model of Phenylketonuria
por: Jung, Sung-Chul, et al.
Publicado: (2008) -
In utero recombinant adeno-associated virus gene transfer in mice, rats, and primates
por: Garrett, Deiadra J, et al.
Publicado: (2003) -
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
por: Arjomandnejad, Motahareh, et al.
Publicado: (2023) -
Recombinant adeno-associated virus 8 vector in gene therapy: Opportunities and challenges
por: Zhao, Liyuan, et al.
Publicado: (2023) -
Pharmacology of Recombinant Adeno-associated Virus Production
por: Penaud-Budloo, Magalie, et al.
Publicado: (2018)